Cell Line : PE-CA-PJ49
Cellosaurus Index : CVCL_2681
Cellosaurus ID : PE-CA-PJ49
CCLE Name
: PECAPJ49_UPPER_AERODIGESTIVE_TRACT
CTRP2 Name
: PECAPJ49
Cancer Type : upper_aerodigestive_tract
Dataset : All
Drug Response Information
Click to show/hide information cards below or download all drug response information.
Information cards below will change according to the dataset selected. The default dataset is “All”, which means information in the cards is based on the integration. If “All” is not selected, information cards will contain drug response information preprocessed for each dataset independently.
Experimental information
Experimental information from All dataset, including cell line name, drug name, and minimum and maximum dosages used in each experiment. Click on Dose-response to query more detail for each experiment.
| Cellosaurus ID | Drug Name | Original Dataset(s) | Min Dose | Max Dose | Dose-response |
|---|---|---|---|---|---|
| PE-CA-PJ49 | 16-beta-bromoandrosterone | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | 1S,3R-RSL-3 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | 3-Cl-AHPC | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | A-804598 | CTRP2 | 0.0041 | 66.0000 |
|
| PE-CA-PJ49 | AA-COCF3 | CTRP2 | 0.0010 | 17.0000 |
|
| PE-CA-PJ49 | ABT737 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | AC55649 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Afatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AGK-2 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Alisertib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | alisertib:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | Alpelisib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | alvocidib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AM-580 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | apicidin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ASN 05257430 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | AT-406 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AT13387 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AT7867 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | austocystin D | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | avicin D | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | avrainvillamide | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Axitinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AZ-3146 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | azacitidine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AZD-7545 | CTRP2 | 0.0023 | 74.0000 |
|
| PE-CA-PJ49 | AZD1480 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AZD6482 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AZD7762 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | AZD8055 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | B02 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | barasertib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | bardoxolone methyl | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Bax channel blocker | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BCL-LZH-4 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Belinostat | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | bendamustine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | betulinic acid | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Bexarotene | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BI-2536 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BIBR-1532 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | birinapant | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BIX-01294 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | bleomycin A2 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BMS-195614 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BMS-270394 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BMS-345541 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BMS-536924 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | BMS-754807 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Bortezomib | CTRP2 | 0.0000 | 0.1300 |
|
| PE-CA-PJ49 | Bosutinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-A02303741 | CTRP2 | 0.0017 | 55.0000 |
|
| PE-CA-PJ49 | BRD-A02303741:carboplatin (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-A02303741:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | BRD-A05715709 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-A71883111 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD-A86708339 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K02251932 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K02492147 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K03536150 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | BRD-K04800985 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K07442505 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K09587429 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K11533227 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K13999467 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K14844214 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K16147474 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K17060750 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K19103580 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K24690302 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K26531177 | CTRP2 | 0.0100 | 330.0000 |
|
| PE-CA-PJ49 | BRD-K28456706 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K29313308 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K33199242 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K34222889 | CTRP2 | 0.0017 | 57.0000 |
|
| PE-CA-PJ49 | BRD-K35604418 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | BRD-K37390332 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD-K41597374 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K42260513 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K45681478 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K48477130 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K50799972 | CTRP2 | 0.0020 | 17.0000 |
|
| PE-CA-PJ49 | BRD-K51490254 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K51831558 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K52037352 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K55116708 | CTRP2 | 0.0020 | 17.0000 |
|
| PE-CA-PJ49 | BRD-K55473186 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K61166597 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K63431240 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K64610608 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD-K66453893 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K66532283 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K70511574 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K71781559 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K71935468 | CTRP2 | 0.0025 | 83.0000 |
|
| PE-CA-PJ49 | BRD-K80183349 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K85133207 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K88742110 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K90370028 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD-K94991378 | CTRP2 | 0.0025 | 83.0000 |
|
| PE-CA-PJ49 | BRD-K97651142 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-K99006945 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD-M00053801 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD1812 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD1835 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | BRD4132 | CTRP2 | 0.0049 | 80.0000 |
|
| PE-CA-PJ49 | BRD55319 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | BRD6340 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD6430 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD8899 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD8958 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | BRD9647 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | BRD9876 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | brefeldin A | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | brivanib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | C6-ceramide | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Cabozantinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | canertinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Carboplatin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | carboplatin:etoposide (40:17 mol-mol) | CTRP2 | 0.0014 | 47.0000 |
|
| PE-CA-PJ49 | carboplatin:UNC0638 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | CAY10576 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | CAY10594 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | CAY10618 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | CBB-1007 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | CCT036477 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | CD-1530 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | CD-437 | CTRP2 | 0.0011 | 18.0000 |
|
| PE-CA-PJ49 | Cediranib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ceranib-2 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | cerulenin | CTRP2 | 0.0045 | 150.0000 |
|
| PE-CA-PJ49 | Ch-55 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | CHEMBL1222381 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | CHEMBL374350 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | CHIR-99021 | CTRP2 | 0.0024 | 80.0000 |
|
| PE-CA-PJ49 | chlorambucil | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | CHM-1 | CTRP2 | 0.0005 | 16.0000 |
|
| PE-CA-PJ49 | ciclopirox | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ciclosporin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | CID-5951923 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | clofarabine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | COL-3 | CTRP2 | 0.0020 | 33.0000 |
|
| PE-CA-PJ49 | Compound 1541A | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | compound 1B | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Compound 23 citrate | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Compound 7d-cis | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | CR-1-31B | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Crizotinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | crizotinib:PLX-4032 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | cucurbitacin I | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | curcumin | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | cytarabine hydrochloride | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | cytochalasin B | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Dabrafenib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Dacarbazine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Dactolisib | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | Daporinad | CTRP2 | 0.0001 | 2.0000 |
|
| PE-CA-PJ49 | Dasatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | DBeQ | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Decitabine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | decitabine:carboplatin (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | decitabine:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | dexamethasone | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Dinaciclib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Docetaxel | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | docetaxel:tanespimycin (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | Doramapimod | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Doxorubicin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | doxorubicin:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | elocalcitol | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Entinostat | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | epigallocatechin-3-monogallate | CTRP2 | 0.0090 | 300.0000 |
|
| PE-CA-PJ49 | erastin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Erlotinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | erlotinib:PLX-4032 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | etomoxir | CTRP2 | 0.0090 | 300.0000 |
|
| PE-CA-PJ49 | Etoposide | CTRP2 | 0.0009 | 28.0000 |
|
| PE-CA-PJ49 | ETP-46464 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Fedratinib | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | fingolimod | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | fluorouracil | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | fluvastatin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Foretinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | FQI-2 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | fumonisin B1 | CTRP2 | 0.0150 | 500.0000 |
|
| PE-CA-PJ49 | GANT-61 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | GDC-0879 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Gefitinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Gemcitabine | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | GMX-1778 | CTRP2 | 0.0000 | 0.3000 |
|
| PE-CA-PJ49 | gossypol | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | GSK-3 inhibitor IX | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | GSK1059615 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | GSK2636771 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | GSK4112 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | GSK461364 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | GW-405833 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | GW843682X | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | HBX-41108 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | HC-067047 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | HLI 373 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | hyperforin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | I-BET-762 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | I-BET151 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Ibrutinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | IC-87114 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Idelalisib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Imatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | importazole | CTRP2 | 0.0061 | 200.0000 |
|
| PE-CA-PJ49 | indisulam | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | IPR-456 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | isoevodiamine | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | isonicotinohydroxamic acid | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ISOX | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ISOX:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | istradefylline | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | itraconazole | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | IU1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | JQ-1:carboplatin (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | JQ-1:MK-0752 (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | JQ-1:navitoclax (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | JQ-1:UNC0638 (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | JQ-1:vorinostat (2:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | JQ1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | JW-480 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | JW-74 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KH-CB19 | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | KHS101 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Ki8751 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Ko-143 | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | KPT185 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KU 0060648 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | KU-0063794 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KU-55933 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KU-60019 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KW-2449 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | KX2-391 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | L-685458 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | Lapatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | LBH-589 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | LE-135 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Lenvatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | leptomycin B | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Linifanib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Linsitinib | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | lomeguatrib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | lovastatin acid | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | LRRK2-IN-1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | LY-2183240 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | manumycin A | CTRP2 | 0.0009 | 30.0000 |
|
| PE-CA-PJ49 | Masitinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Mdivi-1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Merck60 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Methotrexate | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | methylstat | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | MG-132 | CTRP2 | 0.0006 | 20.0000 |
|
| PE-CA-PJ49 | MGCD-265 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | MI-1 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | MI-2 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | MIRA-1 | CTRP2 | 0.0020 | 17.0000 |
|
| PE-CA-PJ49 | mitomycin | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | MK-0752 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | MK-1775 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | MK-2206 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ML006 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | ML030 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ML050 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ML162 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ML203 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | ML210 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | ML239 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ML258 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ML311 | CTRP2 | 0.0010 | 66.0000 |
|
| PE-CA-PJ49 | ML320 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ML334 diastereomer | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | MLN2238 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | MLN2480 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | momelotinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | myricetin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | N9-isopropylolomoucine | CTRP2 | 0.0120 | 400.0000 |
|
| PE-CA-PJ49 | nakiterpiosin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | narciclasine | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Navitoclax | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:birinapant (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:gemcitabine (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:MST-312 (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:piperlongumine (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:pluripotin (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:PLX-4032 (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | navitoclax:sorafenib (1:1 mol-mol) | CTRP2 | 0.0015 | 50.0000 |
|
| PE-CA-PJ49 | necrostatin-1 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | necrostatin-7 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | necrosulfonamide | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Nelarabine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | neratinib | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | niclosamide | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Nilotinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | nintedanib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NPC-26 | CTRP2 | 0.0012 | 40.0000 |
|
| PE-CA-PJ49 | NSC 74859 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | NSC23766 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | NSC30930 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NSC48300 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NSC632839 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Nutlin-3a | CTRP2 | 0.0045 | 150.0000 |
|
| PE-CA-PJ49 | NVP-231 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NVP-ADW742 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NVP-BSK805 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | NVP-TAE684 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | O-6-benzylguanine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Obatoclax Mesylate | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Olaparib | CTRP2 | 0.0045 | 150.0000 |
|
| PE-CA-PJ49 | oligomycin A | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | omacetaxine mepesuccinate | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | OSI-027 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | ouabain | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | Oxaliplatin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PAC-1 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Paclitaxel | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | palmostatin B | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | pandacostat | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | parbendazole | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Parthenolide | CTRP2 | 0.0020 | 33.0000 |
|
| PE-CA-PJ49 | Pazopanib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PD 153035 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | PD318088 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PDMP | CTRP2 | 0.0065 | 210.0000 |
|
| PE-CA-PJ49 | Pevonedistat | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | PF-184 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PF-3758309 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PF-4800567 hydrochloride | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PF-573228 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PF-750 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | PHA-793887 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | phloretin | CTRP2 | 0.0180 | 590.0000 |
|
| PE-CA-PJ49 | PI-103 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | Pictilisib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | pifithrin-alpha | CTRP2 | 0.0071 | 230.0000 |
|
| PE-CA-PJ49 | pifithrin-mu | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | PIK-93 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Piperlongumine | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | piperlongumine:MST-312 (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | pitstop2 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | PL-DI | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Platin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | pluripotin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | PLX-4032 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | PLX-4720 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | PRIMA-1 | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | PRL-3 Inhibitor I | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | procarbazine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | prochlorperazine | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | purmorphamine | CTRP2 | 0.0046 | 150.0000 |
|
| PE-CA-PJ49 | PX-12 | CTRP2 | 0.0030 | 100.0000 |
|
| PE-CA-PJ49 | PYR-41 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | pyrazolanthrone | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Quizartinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | R428 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | RAF265 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Rapamycin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Regorafenib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Repligen 136 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | RG-108 | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | RITA | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | RO4929097 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Ruxolitinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | salermide | CTRP2 | 0.0120 | 400.0000 |
|
| PE-CA-PJ49 | salermide:PLX-4032 (12:1 mol-mol) | CTRP2 | 0.0066 | 220.0000 |
|
| PE-CA-PJ49 | Saracatinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SB-225002 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | SB-431542 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SB-525334 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SB-743921 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SCH-529074 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SCH-79797 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | Selisistat | CTRP2 | 0.0024 | 80.0000 |
|
| PE-CA-PJ49 | Selumetinib | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | selumetinib:BRD-A02303741 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | selumetinib:decitabine (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | selumetinib:GDC-0941 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | selumetinib:JQ-1 (4:1 mol-mol) | CTRP2 | 0.0051 | 170.0000 |
|
| PE-CA-PJ49 | selumetinib:MK-2206 (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| PE-CA-PJ49 | selumetinib:navitoclax (8:1 mol-mol) | CTRP2 | 0.0046 | 75.0000 |
|
| PE-CA-PJ49 | selumetinib:piperlongumine (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| PE-CA-PJ49 | selumetinib:PLX-4032 (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| PE-CA-PJ49 | selumetinib:tretinoin (2:1 mol-mol) | CTRP2 | 0.0061 | 200.0000 |
|
| PE-CA-PJ49 | selumetinib:UNC0638 (4:1 mol-mol) | CTRP2 | 0.0051 | 83.0000 |
|
| PE-CA-PJ49 | selumetinib:vorinostat (8:1 mol-mol) | CTRP2 | 0.0046 | 150.0000 |
|
| PE-CA-PJ49 | semagacestat | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Sepantronium bromide | CTRP2 | 0.0000 | 1.0000 |
|
| PE-CA-PJ49 | Serdemetan | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | serdemetan:SCH-529074 (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SGX-523 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SID 26681509 | CTRP2 | 0.0090 | 300.0000 |
|
| PE-CA-PJ49 | sildenafil | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | silmitasertib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | simvastatin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | sirolimus:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | SJ-172550 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | skepinone-L | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SKI-II | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | SMER-3 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SNS-032 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SNX-2112 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SNX-2112:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | Sorafenib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | sotrastaurin | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | spautin-1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Sphingosine Kinase 1 Inhibitor II | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SR-II-138A | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | SR1001 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | StemRegenin 1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | STF-31 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SU11274 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Sunitinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | SZ4TA2 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | T-5345967 | CTRP2 | 0.0160 | 530.0000 |
|
| PE-CA-PJ49 | tacedinaline | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | tacrolimus | CTRP2 | 0.0023 | 74.0000 |
|
| PE-CA-PJ49 | tamatinib | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Tamoxifen | CTRP2 | 0.0030 | 100.0000 |
|
| PE-CA-PJ49 | tandutinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Tanespimycin | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | tanespimycin:bortezomib (250:1 mol-mol) | CTRP2 | 0.0005 | 17.0000 |
|
| PE-CA-PJ49 | tanespimycin:gemcitabine (1:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Telomerase Inhibitor IX | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | Temozolomide | CTRP2 | 0.0041 | 66.0000 |
|
| PE-CA-PJ49 | TG-100-115 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | TGX221 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Thalidomide | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | tipifarnib-P1 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | tivantinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Tivozanib | CTRP2 | 0.0004 | 13.0000 |
|
| PE-CA-PJ49 | Topotecan | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | tosedostat | CTRP2 | 0.0081 | 270.0000 |
|
| PE-CA-PJ49 | TPCA-1 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Trametinib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Tretinoin | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | tretinoin:carboplatin (2:1 mol-mol) | CTRP2 | 0.0030 | 100.0000 |
|
| PE-CA-PJ49 | tretinoin:navitoclax (4:1 mol-mol) | CTRP2 | 0.0051 | 83.0000 |
|
| PE-CA-PJ49 | triptolide | CTRP2 | 0.0000 | 0.3000 |
|
| PE-CA-PJ49 | TW 37 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | UNC0321 | CTRP2 | 0.0020 | 33.0000 |
|
| PE-CA-PJ49 | UNC0638 | CTRP2 | 0.0010 | 17.0000 |
|
| PE-CA-PJ49 | UNC0638:navitoclax (1:1 mol-mol) | CTRP2 | 0.0010 | 17.0000 |
|
| PE-CA-PJ49 | VAF-347 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | valdecoxib | CTRP2 | 0.0180 | 600.0000 |
|
| PE-CA-PJ49 | vandetanib | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Veliparib | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | VER-155008 | CTRP2 | 0.0011 | 37.0000 |
|
| PE-CA-PJ49 | Vincristine | CTRP2 | 0.0041 | 130.0000 |
|
| PE-CA-PJ49 | vorapaxar | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | Vorinostat | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | vorinostat:carboplatin (1:1 mol-mol) | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | vorinostat:navitoclax (4:1 mol-mol) | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | VU0155056 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | WAY-362450 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | WP1130 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | WZ4002 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | WZ8040 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | XL765 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | YK-4-279 | CTRP2 | 0.0010 | 33.0000 |
|
| PE-CA-PJ49 | YL54 | CTRP2 | 0.0020 | 66.0000 |
|
| PE-CA-PJ49 | zebularine | CTRP2 | 0.0180 | 590.0000 |
|
| PE-CA-PJ49 | ZSTK474 | CTRP2 | 0.0020 | 66.0000 |
|
IC50
IC50 indicates how much drug dosage is needed to inhibit the cells by 50%, in vitro, compared to the control well.
Drugs with highest and lowest IC50
Drugs with highest and lowest IC50
IC90
IC90 indicates how much drug dosage is needed to inhibit the cells by 90%, in vitro, compared to the control well.
Drugs with highest and lowest IC90
Drugs with highest and lowest IC90
AUC
AUC represents the area under a dose-response curve, where 0% indicates no activity and 100% indicates that a drug completely inhibits the cells across testing dosages.
Drugs with highest and lowest AUC
Drugs with highest and lowest AUC